Search

A recent study conducted at Genentech Inc. in South San Francisco evaluated multiple immunoassay formats for the detection of anti-drug antibodies (ADAs) to zinpentraxin alfa, a therapeutic being developed for the treatment of fibrotic diseases. The researchers compared four different assay formats and assessed parameters such as sensitivity, precision, and drug tolerance. They found that the semi-homogeneous ADA assay format without sample pre-treatment was the most suitable for measuring zinpentraxin alpha immunogenicity. The study highlights the importance of selecting the appropriate assay format and sample pre-treatment method for evaluating therapeutic drug immunogenicity. [Extracted from the article]